, Volume 20, Issue 1, pp 70–75 | Cite as

Complications of acromegaly: thyroid and colon

  • Amit Tirosh
  • Ilan Shimon



In acromegaly the long-term exposure to high growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels may result in specific complications in different human organs, including the thyroid gland and the colon.

Materials and Methods

We will review here the evidence available regarding the characteristic thyroid and colon complications in acromegaly.


This review summarizes the published data observing noncancerous structural abnormalities (thyroid nodules, colonic polyps) and thyroid and colon cancer in patients diagnosed with acromegaly.


Thyroid micro-carcinomas are probably over-diagnosed among acromegalic patients. In regard to colon cancer, there is no sufficient data to suggest that colon cancer risk is higher in acromegaly compared to the general population.


Acromegaly Colon Thyroid 


Compliance with ethical standards

Conflict of interest

Amit Tirosh has no conflicts of interest to declare. Ilan Shimon has received research grants, consulting and lectureship fees from Novartis and Pfizer.


  1. 1.
    Cohen P, Clemmons DR, Rosenfeld RG et al (2000) Does the GH–IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 10:297–305. doi: 10.1054/ghir.2000.0171 CrossRefPubMedGoogle Scholar
  2. 2.
    Boguszewski CL, Ayuk J (2016) Management of endocrine disease: acromegaly and cancer: an old debate revisited. Eur J Endocrinol. doi: 10.1530/EJE-16-0178 PubMedCentralGoogle Scholar
  3. 3.
    Renehan AG, Zwahlen M, Minder C et al (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet (London, England) 363:1346–1353. doi: 10.1016/S0140-6736(04)16044-3 CrossRefGoogle Scholar
  4. 4.
    Jenkins PJ, Besser M (2001) Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab 86:2935–2941. doi: 10.1210/jcem.86.7.7634 CrossRefPubMedGoogle Scholar
  5. 5.
    Melmed S (2001) Acromegaly and cancer: Not a problem? J Clin Endocrinol Metab 86:2929–2934. doi: 10.1210/jcem.86.7.7635 CrossRefPubMedGoogle Scholar
  6. 6.
    Roelfsema F, Biermasz NR, Frolich M et al (2009) Diminished and irregular thyrotropin secretion with preserved diurnal rhythm in patients with active acromegaly. J Clin Endocrinol Metab 94:1945–1950. doi: 10.1210/jc.2009-0174 CrossRefPubMedGoogle Scholar
  7. 7.
    Miyakawa M, Saji M, Tsushima T et al (1988) Thyroid volume and serum thyroglobulin levels in patients with acromegaly: correlation with plasma insulin-like growth factor 1 levels. J Clin Endocrinol Metab 67:973–978CrossRefPubMedGoogle Scholar
  8. 8.
    Lamberg BA, Pelkonen R, Aro A, Grahne B (1976) Thyroid function in acromegaly before and after transsphenoidal hypophysectomy followed by cryoapplication. Acta Endocrinol (Copenh) 82:254–266Google Scholar
  9. 9.
    Geelhoed-Duijvestijn PH, Roelfsema F, Schröder-van der Elst JP et al (1992) Effect of administration of growth hormone on plasma and intracellular levels of thyroxine and tri-iodothyronine in thyroidectomized thyroxine-treated rats. J Endocrinol 133:45–49CrossRefPubMedGoogle Scholar
  10. 10.
    Damjanović SS, Petakov MS, Raicević S et al (2000) Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery. J Clin Endocrinol Metab 85:147–154. doi: 10.1210/jcem.85.1.6296 CrossRefPubMedGoogle Scholar
  11. 11.
    Gøtzsche LS, Flyvbjerg A, Marshall S et al (1991) The influence of growth hormone and thyroxine on iodothyronine deiodinase activity in the liver, kidney and brown adipose tissue in hypophysectomized rats. Acta Endocrinol (Copenh) 125:219–226Google Scholar
  12. 12.
    Roelfsema F, Frölich M (1991) Pulsatile thyrotropin release and thyroid function in acromegalics before and during subcutaneous octreotide infusion. J Clin Endocrinol Metab 72:77–82. doi: 10.1210/jcem-72-1-77 CrossRefPubMedGoogle Scholar
  13. 13.
    Wuster C, Steger G, Schmelzle A et al (1991) Increased incidence of euthyroid and hyperthyroid goiters independently of thyrotropin in patients with acromegaly. Horm Metab Res 23:131–134. doi: 10.1055/s-2007-1003632 CrossRefPubMedGoogle Scholar
  14. 14.
    Gasperi M, Martino E, Manetti L et al (2002) Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest 25:240–245. doi: 10.1007/BF03343997 CrossRefPubMedGoogle Scholar
  15. 15.
    Marzullo P, Cuocolo A, Ferone D et al (2000) Cardiac effect of thyrotoxicosis in acromegaly. J Clin Endocrinol Metab 85:1426–1432. doi: 10.1210/jc.85.4.1426 PubMedGoogle Scholar
  16. 16.
    Chanson P, Salenave S, Kamenicky P et al (2009) Acromegaly. Best Pract Res Clin Endocrinol Metab 23:555–574. doi: 10.1016/j.beem.2009.05.010 CrossRefPubMedGoogle Scholar
  17. 17.
    Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–152. doi: 10.1210/er.2002-0022 CrossRefPubMedGoogle Scholar
  18. 18.
    Katznelson L, Laws ER, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933–3951. doi: 10.1210/jc.2014-2700 CrossRefPubMedGoogle Scholar
  19. 19.
    Gatto F, Barbieri F, Castelletti L et al (2011) In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5. Pituitary 14:141–147. doi: 10.1007/s11102-010-0271-2 CrossRefPubMedGoogle Scholar
  20. 20.
    Lamberts SW, Zuyderwijk J, den Holder F et al (1989) Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinology 50:44–50CrossRefPubMedGoogle Scholar
  21. 21.
    Amlashi FG, Tritos NA (2016) Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management. Endocrine. doi: 10.1007/s12020-016-0863-3 PubMedGoogle Scholar
  22. 22.
    Atkinson H, England JA, Rafferty A et al (2013) Somatostatin receptor expression in thyroid disease. Int J Exp Pathol 94:226–229. doi: 10.1111/iep.12024 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Razzore P, Colao A, Baldelli R et al (1999) Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study. Clin Endocrinol (Oxf) 51:159–164. doi: 10.1046/j.1365-2265.1999.00812.x CrossRefGoogle Scholar
  24. 24.
    Carvalho P, Lau E, Carvalho D (2015) Surgery induced hypopituitarism in acromegalic patients: a systematic review and meta-analysis of the results. Pituitary 18:844–860. doi: 10.1007/s11102-015-0661-6 CrossRefPubMedGoogle Scholar
  25. 25.
    Sarkar S, Rajaratnam S, Chacko G, Chacko AG (2014) Endocrinological outcomes following endoscopic and microscopic transsphenoidal surgery in 113 patients with acromegaly. Clin Neurol Neurosurg 126:190–195. doi: 10.1016/j.clineuro.2014.09.004 CrossRefPubMedGoogle Scholar
  26. 26.
    Berkmann S, Fandino J, Müller B et al (2012) Pituitary surgery: experience from a large network in Central Switzerland. Swiss Med Wkly 142:w13680. doi: 10.4414/smw.2012.13680 PubMedGoogle Scholar
  27. 27.
    Haugen BR, Alexander EK, Bible KC et al (2015) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. doi: 10.1089/thy.2015.0020 Google Scholar
  28. 28.
    Tode B, Serio M, Rotella CM et al (1989) Insulin-like growth factor-I: autocrine secretion by human thyroid follicular cells in primary culture. J Clin Endocrinol Metab 69:639–647CrossRefPubMedGoogle Scholar
  29. 29.
    Cheung NW, Boyages SC (1997) The thyroid gland in acromegaly: an ultrasonographic study. Clin Endocrinol (Oxf) 46:545–549. doi: 10.1046/j.1365-2265.1997.1680985.x CrossRefGoogle Scholar
  30. 30.
    Yoshinari M, Tokuyama T, Kuroda T et al (1992) Preserved thyroidal secretion of thyroxine in acromegalic patients with suppressed hypophyseal secretion of thyrotrophin. Clin Endocrinol (Oxf) 36:355–360CrossRefGoogle Scholar
  31. 31.
    Wolinski K, Czarnywojtek A, Ruchala M (2014) Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly—meta-analysis and systematic review. PLoS ONE. doi: 10.1371/journal.pone.0088787 Google Scholar
  32. 32.
    Dagdelen S, Cinar N, Erbas T (2014) Increased thyroid cancer risk in acromegaly. Pituitary 17:299–306. doi: 10.1007/s11102-013-0501-5 CrossRefPubMedGoogle Scholar
  33. 33.
    Balkany C, Cushing GW (1995) An association between acromegaly and thyroid carcinoma. Thyroid 5:47–50. doi: 10.1089/thy.1995.5.47 CrossRefPubMedGoogle Scholar
  34. 34.
    Dos Santos MCC, Nascimento GC, Nascimento AGC et al (2013) Thyroid cancer in patients with acromegaly: a case-control study. Pituitary 16:109–114. doi: 10.1007/s11102-012-0383-y CrossRefPubMedGoogle Scholar
  35. 35.
    Herrmann BL, Baumann H, Janssen OE et al (2004) Impact of disease activity on thyroid diseases in patients with acromegaly: basal evaluation and follow-up. Exp Clin Endocrinol Diabetes 112:225–230. doi: 10.1055/s-2004-817967 CrossRefPubMedGoogle Scholar
  36. 36.
    de Uchoa HBDMP, Lima GAB, Corrêa LL et al (2013) Prevalence of thyroid diseases in patients with acromegaly: experience of a Brazilian center. Arq Bras Endocrinol Metabol 57:685–690CrossRefPubMedGoogle Scholar
  37. 37.
    Gullu BE, Celik O, Gazioglu N, Kadioglu P (2010) Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 13:242–248. doi: 10.1007/s11102-010-0224-9 CrossRefPubMedGoogle Scholar
  38. 38.
    Popovic V, Damjanovic S, Micic D et al (1998) Increased incidence of neoplasia in patients with pituitary adenomas. Clin Endocrinol (Oxf) 49:441–445. doi: 10.1046/j.1365-2265.1998.00536.x CrossRefGoogle Scholar
  39. 39.
    Barzilay J, Heatley GJ, Cushing GW (1991) Benign and malignant tumors in patients with acromegaly. Arch Intern Med 151:1629–1632CrossRefPubMedGoogle Scholar
  40. 40.
    Davies L, Welch HG (2014) Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 140:317–322. doi: 10.1001/jamaoto.2014.1 CrossRefPubMedGoogle Scholar
  41. 41.
    Ito Y, Miyauchi A (2015) Nonoperative management of low-risk differentiated thyroid carcinoma. Curr Opin Oncol 27:15–20. doi: 10.1097/CCO.0000000000000143 CrossRefPubMedGoogle Scholar
  42. 42.
    Renehan AG, Painter JE, Bell GD et al (2005) Determination of large bowel length and loop complexity in patients with acromegaly undergoing screening colonoscopy. Clin Endocrinol (Oxf) 62:323–330. doi: 10.1111/j.1365-2265.2005.02217.x CrossRefGoogle Scholar
  43. 43.
    Wassenaar MJE, Cazemier M, Biermasz NR et al (2010) Acromegaly is associated with an increased prevalence of colonic diverticula: a case-control study. J Clin Endocrinol Metab 95:2073–2079. doi: 10.1210/jc.2009-1714 CrossRefPubMedGoogle Scholar
  44. 44.
    Dutta P, Bhansali A, Vaiphei K et al (2012) Colonic neoplasia in acromegaly: Increased proliferation or deceased apoptosis? Pituitary 15:166–173. doi: 10.1007/s11102-011-0300-9 CrossRefPubMedGoogle Scholar
  45. 45.
    Bogazzi F, Ultimieri F, Raggi F et al (2002) Peroxisome proliferator activated receptor gamma expression is reduced in the colonic mucosa of acromegalic patients. J Clin Endocrinol Metab 87:2403–2406. doi: 10.1210/jcem.87.5.8625 PubMedGoogle Scholar
  46. 46.
    Krzentowska A, Gołkowski F, Bałdys-Waligórska A, Hubalewska-Dydejczyk A (2010) [Gastrointestinal tract polyps in acromegaly patients]. Przegla̧d Lek 67:1266–1269Google Scholar
  47. 47.
    Rokkas T, Pistiolas D, Sechopoulos P et al (2008) Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol 14:3484–3489CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Lois K, Bukowczan J, Perros P et al (2015) The role of colonoscopic screening in acromegaly revisited: review of current literature and practice guidelines. Pituitary 18:568–574. doi: 10.1007/s11102-014-0586-5 CrossRefPubMedGoogle Scholar
  49. 49.
    Dworakowska D, Gueorguiev M, Kelly P et al (2010) Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. Eur J Endocrinol 163:21–28. doi: 10.1530/EJE-09-1080 CrossRefPubMedGoogle Scholar
  50. 50.
    Ron E, Gridley G, Hrubec Z et al (1991) Acromegaly and gastrointestinal cancer. Cancer 68:1673–1677CrossRefPubMedGoogle Scholar
  51. 51.
    Orme SM, McNally RJ, Cartwright RA, Belchetz PE (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730–2734. doi: 10.1210/jcem.83.8.5007 PubMedGoogle Scholar
  52. 52.
    Baris D, Gridley G, Ron E et al (2002) Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 13:395–400. doi: 10.1023/A:1015713732717 CrossRefPubMedGoogle Scholar
  53. 53.
    Terzolo M, Reimondo G, Gasperi M et al (2005) Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. J Clin Endocrinol Metab 90:84–90. doi: 10.1210/jc.2004-0240 CrossRefPubMedGoogle Scholar
  54. 54.
    Kauppinen-Mäkelin R, Sane T, Välimäki MJ et al (2010) Increased cancer incidence in acromegaly—a nationwide survey. Clin Endocrinol (Oxf) 72:278–279. doi: 10.1111/j.1365-2265.2009.03619.x CrossRefGoogle Scholar
  55. 55.
    Petroff D, Tönjes A, Grussendorf M et al (2015) the incidence of cancer among acromegaly patients: results from the German acromegaly registry. J Clin Endocrinol Metab 100:3894–3902. doi: 10.1210/jc.2015-2372 CrossRefPubMedGoogle Scholar
  56. 56.
    Renehan AG, Odwyer ST, Shalet SM (2001) Screening colonoscopy for acromegaly in perspective. Clin Endocrinol (Oxf) 55:731–733CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Institute of Endocrinology, Beilinson HospitalRabin Medical CenterPetah TikvaIsrael
  2. 2.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations